AnaptysBio Inc [ANAB] stock prices are up 5.30% to $40.33 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The ANAB shares have gain 12.34% over the last week, with a monthly amount glided 16.39%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
AnaptysBio Inc [NASDAQ: ANAB] stock has seen the most recent analyst activity on July 22, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $55. Previously, JP Morgan upgraded its rating to Overweight on July 19, 2024, and elevated its price target to $69. On April 16, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $47 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $56 on April 11, 2024. Wedbush upgraded its rating to a Outperform and raised its price target to $34 on March 12, 2024. BTIG Research started tracking with a Buy rating for this stock on February 26, 2024, and assigned it a price target of $55. In a note dated February 21, 2024, Stifel initiated an Buy rating and provided a target price of $50 on this stock.
The stock price of AnaptysBio Inc [ANAB] has been fluctuating between $13.36 and $41.31 over the past year. Currently, Wall Street analysts expect the stock to reach $36.33 within the next 12 months. AnaptysBio Inc [NASDAQ: ANAB] shares were valued at $40.33 at the most recent close of the market. An investor can expect a potential drop of -9.92% based on the average ANAB price forecast.
Analyzing the ANAB fundamentals
The AnaptysBio Inc [NASDAQ:ANAB] reported sales of 30.47M for trailing twelve months, representing a surge of 217.08%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -5.33%, Pretax Profit Margin comes in at -5.58%, and Net Profit Margin reading is -5.58%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -2.56 and Total Capital is -0.42. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of36.83.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 38.97 points at the first support level, and at 37.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 41.20, and for the 2nd resistance point, it is at 42.06.
Ratios To Look Out For
It’s worth pointing out that AnaptysBio Inc [NASDAQ:ANAB]’s Current Ratio is 9.09. On the other hand, the Quick Ratio is 9.09, and the Cash Ratio is 1.78. Considering the valuation of this stock, the price to sales ratio is 39.97, the price to book ratio is 112.00.
Transactions by insiders
Recent insider trading involved Lizzul Paul F., Chief Medical Officer, that happened on Aug 14 ’24 when 2000.0 shares were sold. 10% Owner, EcoR1 Capital, LLC completed a deal on Aug 14 ’24 to buy 0.27 million shares. Meanwhile, Officer PAUL F LIZZUL bought 2000.0 shares on Aug 14 ’24.
